IceCure Medical ICCM introduced interim outcomes from its ICESECRET kidney most cancers cryoablation examine on the European Affiliation of Urology Convention in Spain. The examine reported an 88.7% recurrence-free charge, highlighting the potential of its minimally invasive know-how as a substitute for conventional therapies.
This promising knowledge reinforces IceCure’s place within the medical know-how house, strengthening confidence in its cryoablation options. As the corporate advances scientific analysis, these outcomes may play a key function in increasing adoption and regulatory approvals worldwide.
Probably Pattern of the ICCM Inventory Following the Information
Following the announcement, shares of the corporate have tumbled 11.2% and closed at $1.10 yesterday. Yesterday, ICCM reported its 2024 outcomes, whereby the corporate’s web loss has elevated 5% 12 months over 12 months. Nevertheless, previously six months, ICCM’s shares have surged 81.2% towards the industry’s 12.7% decline. The S&P 500 has fallen 0.5% in the identical timeframe.
In the meantime, the ICESECRET examine’s robust outcomes exhibiting an 88.7% recurrence-free charge for kidney most cancers cryoablation can enhance the inventory in the long term by rising confidence in its know-how. If extra docs and hospitals undertake this minimally invasive therapy, the corporate may see larger revenues and potential partnerships. Optimistic scientific knowledge additionally improves the probabilities of regulatory approvals, which may open doorways to bigger markets. As consciousness and demand develop, traders could view IceCure as a robust participant within the medical-tech house, driving long-term inventory worth.
In the meantime, ICCM presently has a market capitalization of $63.3 million. The corporate expects an earnings development of 10.7% in 2025.
Picture Supply: Zacks Funding Analysis
Extra on ICCM’s ICESECRET Cryoablation Research Outcomes
The ICESECRET examine is an ongoing scientific trial carried out by IceCure Medical to guage the efficacy and security of its cryoablation know-how for treating small renal plenty (“SRMs”), generally related to early-stage kidney most cancers. Cryoablation is a minimally invasive process that makes use of excessive chilly to destroy cancerous tissues.
The examine demonstrated that cryoablation is a viable different to surgical resection, the normal methodology for treating SRMs, notably for tumors lower than or equal to three cm. Among the many 111 sufferers evaluated over a median follow-up of roughly three years, the recurrence-free charge was 88.7% for these with low-risk tumors and profitable procedures. Sufferers with tumors lower than or equal to three cm at low threat had a recurrence-free charge of 87.8% at a 3.4-year follow-up, whereas these with tumors lower than or equal to three cm total had a recurrence-free charge of 87.2% at 3.5 years. Security knowledge confirmed 17 delicate hostile occasions, three average occasions and a extreme complication. The examine’s affected person group had a imply age of 69, with 84.2% having comorbidities, the most typical being hypertension (77%) and diabetes (47%). These findings spotlight the potential of cryoablation as a protected and efficient different to surgical procedure for kidney most cancers therapy.
Favorable Trade Prospects for ICCM
Per a report by Verified Market Studies, the worldwide cryoablation for most cancers market measurement was valued at $3.5 Billion in 2024 and is forecasted to develop at a CAGR of 6.1% from 2026 to 2033, reaching $5.8 Billion by 2033.
The cryoablation market is experiencing robust development, fueled by the rising incidence of most cancers, an getting old inhabitants and improvements in cryotherapy. A serious driver of this enlargement is the rising adoption of cryoablation for smaller tumors, because it affords fewer unwanted side effects in comparison with conventional therapies.
ICCM’s Zacks Rank & Shares to Contemplate
ICCM carries a Zacks Rank #3 (Maintain) at current.
Some better-ranked shares within the broader medical house are Masimo MASI, Boston Scientific BSX and Cardinal Well being CAH. At current, Masimo sports activities a Zacks Rank #1 (Robust Purchase), whereas Boston Scientific and Cardinal Well being carry a Zacks Rank #2 (Purchase) every. You’ll be able to see the complete list of today’s Zacks #1 Rank stocks here.
Masimo’s shares have rallied 30.1% previously 12 months. Estimates for MASI’s 2024 earnings per share (EPS) have elevated 1.2% to $4.10 previously 30 days. Masimo’s earnings beat estimates in every of the trailing 4 quarters, the typical shock being 17.1%. Within the final reported quarter, it posted an earnings shock of 16.6%.
Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 previously 30 days. Shares of the corporate have surged 56.7% previously 12 months in contrast with the trade’s development of 12.5%. BSX’s earnings surpassed estimates in every of the trailing 4 quarters, the typical shock being 8.25%. Within the final reported quarter, it delivered an earnings shock of seven.69%.
Estimates for Cardinal Well being’s fiscal 2025 EPS have elevated 1.5% to $7.94 previously 30 days. Shares of the corporate have gained 15.2% previously 12 months towards the trade’s 4.1% decline. CAH’s earnings surpassed estimates in every of the trailing 4 quarters, the typical shock being 9.6%. Within the final reported quarter, it delivered an earnings shock of 10.3%.
Zacks’ Analysis Chief Names “Inventory Most More likely to Double”
Our crew of specialists has simply launched the 5 shares with the best chance of gaining +100% or extra within the coming months. Of these 5, Director of Analysis Sheraz Mian highlights the one inventory set to climb highest.
This high choose is among the many most progressive monetary companies. With a fast-growing buyer base (already 50+ million) and a various set of innovative options, this inventory is poised for large features. In fact, all our elite picks aren’t winners however this one may far surpass earlier Zacks’ Shares Set to Double like Nano-X Imaging which shot up +129.6% in little greater than 9 months.
Free: See Our Top Stock And 4 Runners Up
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
Cardinal Health, Inc. (CAH) : Free Stock Analysis Report
Masimo Corporation (MASI) : Free Stock Analysis Report
IceCure Medical Ltd. (ICCM) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
